featured-image

NEW TAIPEI CITY, Taiwan , May 30, 2024 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced its participation in this year's BIO International Convention, which is being held in San Diego, CA , June 3-6, 2024 . "We are excited to engage with potential partners at BIO to showcase our differentiated clinical stage targeted cancer treatments that focus on sugar molecules.

GNX102, our lead antibody-drug conjugate (ADC) candidate, has demonstrated promise for difficult-to-treat cancers such as gastric and bladder cancer. Since our inception, partnering has been a cornerstone of our strategy and business model, and we look forward to exploring new opportunities to advance our mission at BIO," commented Dr. Mei-Chun Yang , CEO of GlycoNex.



During the conference, Dr. Yang will conduct one-on-one meetings with pharmaceutical executives to explore partnering and strategic opportunities for the Company's robust anti-cancer pipeline, specifically GNX102, its lead asset. About GlycoNex Inc.

GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAB) designed to target abnormal sugar molecules in cancer cells.

GNX-102 has success.

Back to Health Page